Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Thursday, June 13, 2024 | Back issues
Courthouse News Service Courthouse News Service


PHILADELPHIA - Blue Cross Blue Shield claims GlaxoSmithKline keeps its $1.3 billion annual monopoly on Wellbutrin SR (bupropion) through "fraudulent statements to patent examiners" and "filing baseless patent infringement actions" against generic manufacturers.

Categories / Uncategorized

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.